Virpax Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$97.75
-0.0
-110.75
2
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-17. The firm is focused on developing novel and proprietary drug delivery systems across various pain indications. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
emptyResult
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-17. The firm is focused on developing novel and proprietary drug delivery systems across various pain indications. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
Recently from Cashu
Virpax Pharmaceuticals Advances Pain Management Innovations at Industry Conference
Virpax Pharmaceuticals Showcases Innovations in Pain Management at Key Industry Conference Virpax Pharmaceuticals, Inc., a company dedicated to developing non-addictive pain management solutions and t…
Virpax Pharmaceuticals Raises $6 Million to Advance Non-Opioid Pain Management Solutions
Virpax Pharmaceuticals Secures Funding to Enhance Pain Management Solutions Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company focused on innovative drug delivery systems for pai…
Virpax Pharmaceuticals Secures $6 Million for Probudur Development and Drug Delivery Innovations
Virpax Pharmaceuticals Expands Funding for Probudur Development Virpax Pharmaceuticals, Inc. announces the successful closure of a public offering, raising $6 million through the sale of common stock…
Virpax Pharmaceuticals Leverages AI for Innovation and Efficiency in Healthcare Solutions
Virpax Pharmaceuticals Embraces AI to Drive Innovation and Efficiency Virpax Pharmaceuticals stands at the forefront of innovation in the pharmaceutical industry, integrating artificial intelligence (…